| Serial Number | 97931795 |
| Word Mark | NEURO-Q |
| Filing Date | Thursday, May 11, 2023 |
| Status | 602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE |
| Status Date | Tuesday, May 28, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Silk protein hydrolysates for use in the manufacture of nutritional supplements |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, May 16, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | US PHARMATECH NV INC. |
| Party Type | 11 - New Owner Before Publication |
| Legal Entity Type | 03 - Corporation |
| Address | LAS VEGAS, NV 89113 |
| Party Name | US Pharmatech Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Torrance, CA 90505 |
| Event Date | Event Description |
| Wednesday, December 27, 2023 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Monday, May 15, 2023 | NEW APPLICATION ENTERED |
| Tuesday, May 16, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, February 5, 2024 | ASSIGNED TO EXAMINER |
| Monday, February 12, 2024 | NON-FINAL ACTION WRITTEN |
| Monday, February 12, 2024 | NON-FINAL ACTION E-MAILED |
| Monday, February 12, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, May 28, 2024 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Tuesday, May 28, 2024 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |